Mufg Securities Americas Inc. Invests $270,000 in Insulet Co. (NASDAQ:PODD)

Mufg Securities Americas Inc. purchased a new stake in Insulet Co. (NASDAQ:PODD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,036 shares of the medical instruments supplier's stock, valued at approximately $270,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. SBI Securities Co. Ltd. acquired a new position in shares of Insulet during the fourth quarter worth $36,000. Itau Unibanco Holding S.A. bought a new stake in Insulet in the fourth quarter valued at $42,000. SRS Capital Advisors Inc. increased its stake in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares in the last quarter. Assetmark Inc. increased its stake in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Insulet by 117.3% during the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after acquiring an additional 149 shares in the last quarter.

Analyst Ratings Changes

PODD has been the topic of a number of research analyst reports. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a research note on Monday, April 28th. Stifel Nicolaus increased their target price on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Royal Bank of Canada assumed coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 target price on the stock. Raymond James reissued an "outperform" rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, Oppenheimer increased their target price on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $306.53.

Insider Activity

In other Insulet news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president now owns 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Trading Up 0.5%

PODD stock traded up $1.63 during mid-day trading on Tuesday, reaching $327.47. 998,435 shares of the stock traded hands, compared to its average volume of 708,069. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a one year low of $170.67 and a one year high of $328.84. The business has a 50-day moving average price of $265.69 and a two-hundred day moving average price of $267.57. The stock has a market capitalization of $23.05 billion, a PE ratio of 56.56, a PEG ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company's revenue was up 28.8% compared to the same quarter last year. During the same period last year, the business earned $0.73 EPS. Equities research analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.